
H Dalton King

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1717146/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chemical Modification of Linkers Provides Stable Linker–Payloads for the Generation of Antibody–Drug Conjugates. ACS Medicinal Chemistry Letters, 2020, 11, 2190-2194.	2.8	19
2	Design and synthesis of a novel series of 4-heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1261-1266.	2.2	8
3	BMS-933043, a Selective $\hat{I}\pm7$ nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia. ACS Medicinal Chemistry Letters, 2017, 8, 366-371.	2.8	12
4	Development of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists. ACS Medicinal Chemistry Letters, 2017, 8, 133-137.	2.8	12
5	Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning. PLoS ONE, 2017, 12, e0187609.	2.5	10
6	The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia. PLoS ONE, 2016, 11, e0159996.	2.5	28
7	Design and Synthesis of a New Series of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure–Activity Relationship. Journal of Medicinal Chemistry, 2016, 59, 11171-11181.	6.4	16
8	Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains. Neuropsychopharmacology, 2016, 41, 568-577.	5.4	19
9	The qEEG Signature of Selective NMDA NR2B Negative Allosteric Modulators; A Potential Translational Biomarker for Drug Development. PLoS ONE, 2016, 11, e0152729.	2.5	19